Why Has Humana (HUM) Declined 8.5% Following Its Most Recent Earnings Announcement?

Humana Stock Performance Since Last Earnings Report

In the month following its most recent earnings announcement, Humana (HUM) has seen its share price decline by approximately 8.5%, lagging behind the broader S&P 500 index.

Assessing the Recent Downtrend

As Humana approaches its next earnings release, investors are questioning whether the current negative momentum will persist or if a rebound is on the horizon. To better understand the situation, let’s review the company’s latest financial results and the factors influencing its performance.

Fourth Quarter Highlights: Loss Narrows, Revenue Rises

For the fourth quarter of 2025, Humana reported an adjusted loss of $3.96 per share. This result was slightly better than the anticipated loss of $4.01 per share, but worse than the $2.16 per share loss recorded in the same quarter last year.

Adjusted revenue climbed 11.8% year-over-year to $32.6 billion, exceeding consensus expectations by 2.4%.

The quarter’s performance was bolstered by increased premiums and strong results from the CenterWell division, particularly in pharmacy and primary care. However, these gains were partially offset by higher operating costs, a significant reduction in investment income, and a decrease in total medical membership.

Operational Overview for Q4

• Premiums reached $30.9 billion, up 11.3% from the previous year, surpassing both consensus and internal estimates.
• Service revenue surged 28.6% to $1.5 billion, also beating expectations.
• Investment income dropped sharply by 55.6% to $132 million, falling short of projections.
• The benefit ratio increased to 93%, up 150 basis points year-over-year.
• Total operating expenses rose 12% to $33.3 billion, higher than anticipated.
• The adjusted operating cost ratio improved by 20 basis points to 13%.
• Net loss widened to $776 million, compared to a $683 million loss a year earlier.

Segment Performance

Insurance Segment

• Adjusted revenue for the segment grew 11.3% to $31.3 billion, driven by higher per-member premiums in Medicare and state-based contracts, as well as growth in stand-alone prescription drug plans.
• The segment posted an adjusted operating loss of $923 million, deeper than last year’s $575 million loss.
• The benefit ratio worsened by 120 basis points to 93.1%.
• The operating cost ratio improved by 20 basis points to 10.8%.
• Total medical membership stood at 15 million as of December 31, 2025, down 8.2% year-over-year and below expectations.

CenterWell Segment

• Quarterly revenue reached $6 billion, up 16.2% year-over-year and above consensus estimates, thanks to strong pharmacy and primary care results.
• Adjusted operating income fell 10.4% to $345 million.
• The operating cost ratio rose by 170 basis points to 94.2%, impacted by the v28 risk model update and higher volumes in specialty pharmacy.

Financial Position as of December 31, 2025

• Cash and cash equivalents totaled $4.2 billion, an 89.1% increase from the end of 2024.
• Total assets grew 5.2% to $48.9 billion.
• Long-term debt increased 11% to $12.4 billion.
• Debt to capitalization improved by 80 basis points to 41.1%.
• Stockholders’ equity rose 7.8% to $17.7 billion.
• Net cash from operations was $921 million, a 68.9% decrease from the prior year.

Capital Allocation in 2025

• Share repurchases totaled $151 million.
• Dividend payments amounted to $430 million.

Full-Year 2025 Results

• Adjusted revenue reached $129.8 billion, up 10.7% year-over-year.
• Adjusted earnings per share increased 5.7% to $17.14.
• Premiums rose 9.6% to $122.8 billion.
• The benefit ratio for the year was 90.2%, up 40 basis points from the previous year.

2026 Outlook

• Revenue is projected to be at least $160 billion, representing a 23.4% increase over 2025.
• The Insurance segment is expected to generate at least $155 billion in revenue, while CenterWell is forecasted to bring in at least $25 billion.
• Adjusted EPS is anticipated to be no less than $9.00, a 47.5% decrease from 2025. GAAP EPS is expected to be at least $8.89.
• Individual Medicare Advantage membership is projected to grow by about 25%.
• Group Medicare Advantage membership is expected to rise by approximately 150,000 members.
• Individual Medicare stand-alone PDP membership could increase by around 1 million.
• State-based contracts are forecasted to add between 25,000 and 100,000 members.
• The Insurance segment’s GAAP benefit ratio is estimated at 92.75% (±25 basis points), and the consolidated adjusted operating cost ratio is expected to be 10% (±25 basis points).
• GAAP operating cash flow is projected between $2.5 and $2.9 billion, with capital expenditures around $650 million.
• The adjusted effective tax rate is expected to be about 25.5%, and the average share count is anticipated to be roughly 121 million.

Trends in Analyst Estimates

Since the last earnings report, analyst forecasts for Humana have generally moved lower, reflecting a more cautious outlook.

VGM Score Breakdown

• Growth Score: D (below average)
• Momentum Score: C (average)
• Value Score: A (top quintile for value investors)
• Overall VGM Score: C

If you’re not committed to a single investment style, the composite VGM Score may be most relevant for your decision-making.

Forward-Looking Perspective

Analyst estimates for Humana have been revised downward, suggesting a less optimistic near-term outlook. The stock currently holds a Zacks Rank #3 (Hold), indicating expectations for performance in line with the broader market over the coming months.

Industry Comparison: Molina Healthcare

Humana operates within the Zacks Medical - HMOs sector. Another company in this space, Molina (MOH), has seen its shares climb 17.7% over the past month. Molina’s most recent quarterly report showed revenue of $11.38 billion, an 8.3% increase year-over-year, but earnings per share fell to -$2.75 from $5.05 a year ago.

For the current quarter, Molina is projected to earn $2.16 per share, a 64.5% decrease from the same period last year. Over the past month, consensus estimates for Molina’s earnings have dropped by 40.6%. The stock holds a Zacks Rank #5 (Strong Sell) and a VGM Score of F.